260 related articles for article (PubMed ID: 38779175)
1. Novel Biomarkers for Alzheimer's Disease: Plasma Neurofilament Light and Cerebrospinal Fluid.
Abukuri DN
Int J Alzheimers Dis; 2024; 2024():6668159. PubMed ID: 38779175
[TBL] [Abstract][Full Text] [Related]
2. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
3. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
Olsson B; Lautner R; Andreasson U; Öhrfelt A; Portelius E; Bjerke M; Hölttä M; Rosén C; Olsson C; Strobel G; Wu E; Dakin K; Petzold M; Blennow K; Zetterberg H
Lancet Neurol; 2016 Jun; 15(7):673-684. PubMed ID: 27068280
[TBL] [Abstract][Full Text] [Related]
4. A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood.
Blennow K
Neurol Ther; 2017 Jul; 6(Suppl 1):15-24. PubMed ID: 28733960
[TBL] [Abstract][Full Text] [Related]
5. Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer's disease dementia in Chinese individuals.
Sun Q; Ni J; Wei M; Long S; Li T; Fan D; Lu T; Shi J; Tian J
Front Aging Neurosci; 2022; 14():963845. PubMed ID: 36062146
[TBL] [Abstract][Full Text] [Related]
6. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
[TBL] [Abstract][Full Text] [Related]
7. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.
Mattsson N; Insel PS; Palmqvist S; Portelius E; Zetterberg H; Weiner M; Blennow K; Hansson O;
EMBO Mol Med; 2016 Oct; 8(10):1184-1196. PubMed ID: 27534871
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid neurofilament light chain and total-tau as biomarkers of neurodegeneration in Alzheimer's disease and frontotemporal dementia.
Giuffrè GM; Quaranta D; Costantini EM; Citro S; Martellacci N; De Ninno G; Vita MG; Guglielmi V; Rossini PM; Calabresi P; Marra C
Neurobiol Dis; 2023 Oct; 186():106267. PubMed ID: 37652185
[TBL] [Abstract][Full Text] [Related]
10. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
[TBL] [Abstract][Full Text] [Related]
11. The dynamics of plasma biomarkers across the Alzheimer's continuum.
Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT
Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875
[TBL] [Abstract][Full Text] [Related]
12. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
[TBL] [Abstract][Full Text] [Related]
13. Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease.
Leuzy A; Cullen NC; Mattsson-Carlgren N; Hansson O
Curr Opin Neurol; 2021 Apr; 34(2):266-274. PubMed ID: 33470669
[TBL] [Abstract][Full Text] [Related]
14. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease.
Pereira JB; Westman E; Hansson O;
Neurobiol Aging; 2017 Oct; 58():14-29. PubMed ID: 28692877
[TBL] [Abstract][Full Text] [Related]
15. Performance of Plasma Amyloid β, Total Tau, and Neurofilament Light Chain in the Identification of Probable Alzheimer's Disease in South China.
Jiao B; Liu H; Guo L; Liao X; Zhou Y; Weng L; Xiao X; Zhou L; Wang X; Jiang Y; Yang Q; Zhu Y; Zhou L; Zhang W; Wang J; Yan X; Tang B; Shen L
Front Aging Neurosci; 2021; 13():749649. PubMed ID: 34776933
[No Abstract] [Full Text] [Related]
16. Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment.
Giacomucci G; Mazzeo S; Bagnoli S; Ingannato A; Leccese D; Berti V; Padiglioni S; Galdo G; Ferrari C; Sorbi S; Bessi V; Nacmias B
J Neurol; 2022 Aug; 269(8):4270-4280. PubMed ID: 35288777
[TBL] [Abstract][Full Text] [Related]
17. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
[TBL] [Abstract][Full Text] [Related]
18. Associations of Neurodegeneration Biomarkers in Cerebrospinal Fluid with Markers of Alzheimer's Disease and Vascular Pathology.
Shir D; Mielke MM; Hofrenning EI; Lesnick TG; Knopman DS; Petersen RC; Jack CR; Algeciras-Schimnich A; Vemuri P; Graff-Radford J
J Alzheimers Dis; 2023; 92(3):887-898. PubMed ID: 36806507
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease.
Dhiman K; Gupta VB; Villemagne VL; Eratne D; Graham PL; Fowler C; Bourgeat P; Li QX; Collins S; Bush AI; Rowe CC; Masters CL; Ames D; Hone E; Blennow K; Zetterberg H; Martins RN
Alzheimers Dement (Amst); 2020; 12(1):e12005. PubMed ID: 32211500
[TBL] [Abstract][Full Text] [Related]
20. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
